Jewelweed – Impatiens capensis

by | Dec 19, 2023 | Jewelweed

How Can We Help?
You are here:
< Back

Evenamide (INNTooltip International Nonproprietary Name) (developmental code names NW-3509, NW-3509A)[1] is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[2][3][4][5] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[4] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[6]

The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy[7] and according to the company, it shows benefit to the management of schizophrenia to poorly responded treatment with antipsychotics. It acts exclusively through glutamatergic inhibition.

Clinical studies

In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023.[8]

The 4 week placebo trial of 2021 to evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide for people with chronic schizophrenia was selected to address patients who are receiving treatment at constant doses of one of the following atypical antipsychotics: aripiprazole, clozapine, quetiapine, olanzapine, paliperidone or risperidone.[9][10]

See also

References

  1. ^ Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G (February 2024). "Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia". The International Journal of Neuropsychopharmacology. 27 (2): pyae005. doi:10.1093/ijnp/pyae005. PMC 10858345. PMID 38195245.
  2. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.
  3. ^ Kemp MI (2010). "Structural trends among second-generation voltage-gated sodium channel blockers". Progress in Medicinal Chemistry. 49: 81–111. doi:10.1016/S0079-6468(10)49003-7. PMID 20855039.
  4. ^ a b Zuliani V, Amori L, Rivara M (21 June 2011). "Advances in Design of Development of Sodium Channel Blockers". In Gupta SP (ed.). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
  5. ^ Zuliani V, Amori L, Rivara M (2011). "Advances in Design and Development of Sodium Channel Blockers". Ion Channels and Their Inhibitors. pp. 79–115. doi:10.1007/978-3-642-19922-6_4. ISBN 978-3-642-19921-9.
  6. ^ "Newron raised new funds to continue the development of Neurological therapies". Labiotech. 5 February 2015. Archived from the original on 4 March 2016.
  7. ^ "Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients". Newron Pharmaceuticals. Retrieved 2024-06-28.
  8. ^ "Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)". Newron Pharmaceuticals. 2024-01-04. Retrieved 2024-01-04.
  9. ^ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-06-28.
  10. ^ "Evenamide: New Positive Results From Study 008A". Psychiatric Times. 2024-04-30. Retrieved 2024-06-28.

External links

Categories
Table of Contents